BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/19/2026 7:13:09 AM | Browse: 1 | Download: 13
 |
Received |
|
2026-01-19 03:45 |
|
Peer-Review Started |
|
2026-01-19 10:15 |
|
First Decision by Editorial Office Director |
|
2026-02-02 08:58 |
|
Return for Revision |
|
2026-02-02 08:58 |
|
Revised |
|
2026-02-10 23:36 |
|
Publication Fee Transferred |
|
2026-02-12 20:12 |
|
Second Decision by Editor |
|
2026-04-01 02:44 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-01 07:49 |
|
Articles in Press |
|
2026-04-01 07:49 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-12 00:49 |
|
Publish the Manuscript Online |
|
2026-05-19 07:13 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Cardiovascular safety of proton pump inhibitors in post-percutaneous coronary intervention patients receiving dual antiplatelet therapy: A meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rohab Sohail, Zaraq Khan, Haider Hussain Shah, Ridda Khattak, Azeem Khan, Shahryar Chaudhry, Uzair Khan, Hafsa Mansoor, Fnu Namal, Jason Orciuolo, Sahil Desai and Manjeet Singh |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Rohab Sohail, MD, Internal Medicine, Bayhealth Medical Center, 640 South State Street, Dover, DE 19904, United States. rohabsohail98@gmail.com |
| Key Words |
Proton pump inhibitors; Dual antiplatelet therapy; Percutaneous coronary intervention; Major cardiovascular adverse events; Cardiac revascularization |
| Core Tip |
This meta-analysis provides a robust, clinically relevant evaluation of proton pump inhibitor use in patients receiving dual antiplatelet therapy after PCI by integrating evidence from both randomized trials and real-world observational studies. Importantly, it demonstrates that concerns regarding impaired antiplatelet efficacy do not translate into increased risks of acute coronary syndrome, mortality, stent thrombosis, or stroke in randomized data, suggesting that adverse signals seen in observational studies likely reflect residual confounding rather than true harm. These findings shift the focus from theoretical drug–drug interactions to patient-centered clinical outcomes and support the safe, guideline-concordant use of PPIs for gastrointestinal protection in appropriately selected post-PCI patients. |
| Publish Date |
2026-05-19 07:13 |
| Citation |
Sohail R, Khan Z, Shah HH, Khattak R, Khan A, Chaudhry S, Khan U, Mansoor H, Namal F, Orciuolo J, Desai S, Singh M. Cardiovascular safety of proton pump inhibitors in post-percutaneous coronary intervention patients receiving dual antiplatelet therapy: A meta-analysis. World J Cardiol 2026; 18(5): 119100 |
| URL |
https://www.wjgnet.com/1949-8462/full/v18/i5/119100.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v18.i5.119100 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
